Show Summary Details
Page of

Metastatic Melanoma: Targeted Therapy 

Metastatic Melanoma: Targeted Therapy
Chapter:
Metastatic Melanoma: Targeted Therapy
Author(s):

Kathryn Baksh

and Ragini R. Kudchadkar

DOI:
10.1093/med/9780199971015.003.0009
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 September 2019

Transformation into melanoma is thought to occur due to the accumulation of mutations in growth-regulating genes, the loss of adhesion receptors, and the increase in autocrine and paracrine growth factors; all of which contribute to uncontrolled proliferation promoting the survival of these abnormal cells. In addition, chemotherapy alone has not been able to proven to improve overall survival for patients with this disease. These circumstances set the stage for the exploration into the melanoma genome and the development of novel targeted agents to manipulate the respective molecular pathways. Further understanding of resistance mechanisms will lead to more combination trials, both with other signal transduction inhibitors and with immune therapies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.